Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded at Argus

Argus upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from a hold rating to a buy rating in a research note published on Thursday, MarketBeat Ratings reports. Argus currently has $850.00 price target on the biopharmaceutical company’s stock.

A number of other equities research analysts also recently weighed in on the company. Citigroup raised their price objective on Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the company a “neutral” rating in a research report on Monday, August 3rd. Sanford C. Bernstein upgraded shares of Regeneron Pharmaceuticals to a “hold” rating in a report on Wednesday, July 29th. Zacks Research raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, September 28th. Cantor Fitzgerald boosted their price objective on shares of Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. Finally, Morgan Stanley increased their target price on shares of Regeneron Pharmaceuticals from $730.00 to $758.00 and gave the company an “equal weight” rating in a research report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have given a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $809.50.

Regeneron Pharmaceuticals Stock Up 0.1%

Regeneron Pharmaceuticals stock opened at $735.20 on Thursday. The business has a fifty day moving average of $788.30 and a two-hundred day moving average of $720.93. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06. The firm has a market cap of $75.70 billion, a P/E ratio of 18.17, a P/E/G ratio of 1.41 and a beta of 0.16. Regeneron Pharmaceuticals has a twelve month low of $541.00 and a twelve month high of $859.34.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.16 by $4.13. The business had revenue of $4.29 billion for the quarter, compared to the consensus estimate of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The business’s revenue was up 16.7% compared to the same quarter last year. During the same period last year, the business posted $12.81 EPS. On average, analysts forecast that Regeneron Pharmaceuticals will post 45.34 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th were paid a dividend of $0.94 per share. The ex-dividend date was Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is presently 9.29%.

Insider Transactions at Regeneron Pharmaceuticals

In related news, Director Kathryn Guarini sold 400 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total value of $340,000.00. Following the completion of the sale, the director directly owned 603 shares in the company, valued at $512,550. This trade represents a 39.88% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marion Mccourt sold 1,131 shares of the business’s stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $857.39, for a total transaction of $969,708.09. Following the sale, the executive vice president directly owned 12,003 shares in the company, valued at approximately $10,291,252.17. This represents a 8.61% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 3,946 shares of company stock worth $3,302,458. Insiders own 6.97% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Arjuna Capital grew its stake in Regeneron Pharmaceuticals by 3.2% in the first quarter. Arjuna Capital now owns 457 shares of the biopharmaceutical company’s stock valued at $353,000 after acquiring an additional 14 shares during the period. MCF Advisors LLC raised its position in shares of Regeneron Pharmaceuticals by 50.0% during the fourth quarter. MCF Advisors LLC now owns 45 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 15 shares during the period. Boyd Watterson Asset Management LLC OH raised its position in shares of Regeneron Pharmaceuticals by 1.4% during the first quarter. Boyd Watterson Asset Management LLC OH now owns 1,087 shares of the biopharmaceutical company’s stock worth $840,000 after purchasing an additional 15 shares during the period. Geneos Wealth Management Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 1.8% during the 1st quarter. Geneos Wealth Management Inc. now owns 835 shares of the biopharmaceutical company’s stock valued at $645,000 after purchasing an additional 15 shares in the last quarter. Finally, Aaron Wealth Advisors LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 1.5% during the 1st quarter. Aaron Wealth Advisors LLC now owns 1,102 shares of the biopharmaceutical company’s stock valued at $851,000 after purchasing an additional 16 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Sanofi alliance expanded, with substantial upfront and milestone potential. Sanofi will pay Regeneron $1 billion upfront and up to $7 billion in additional milestones for four next-generation, long-acting antibodies targeting type 2 inflammation. The companies will share development and commercialization costs and future profits, strengthening Regeneron’s immunology pipeline beyond Dupixent. Sanofi pays Regeneron up to $8B to expand immunology alliance
• Positive Sentiment: Weight-loss combination data address a key GLP-1 concern. In the Phase 2 COURAGE trial, trevogrumab preserved approximately 70% of the muscle lost by patients receiving semaglutide alone in an MRI substudy. The result could give Regeneron a differentiated position in the obesity market, although additional development and regulatory work remain. Phase 2 COURAGE Trial results
• Positive Sentiment: Analysts became more constructive. Jefferies raised its price target to $930 and maintained a buy rating, while Argus upgraded REGN to buy with an $850 target. These actions suggest improved confidence in the company’s pipeline and longer-term growth prospects.
• Neutral Sentiment: Ubamatamab showed promising but early oncology results. The therapy produced a 73% objective response rate and 11-month median progression-free survival in 11 heavily pretreated patients with low-grade serous ovarian cancer. The small, early-stage dataset is encouraging but requires confirmation in larger studies. Ubamatamab ovarian cancer study
• Negative Sentiment: Investors appeared underwhelmed by the ovarian cancer data. Despite the high response rate, reports indicated that REGN came under pressure after the early-stage readout, likely reflecting concerns about the limited patient sample, durability, and the distance to possible approval.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses human genetics, antibody technology and other biological research platforms to develop treatments in areas including eye diseases, cancer, cardiovascular and metabolic disorders, inflammatory diseases, infectious diseases and rare conditions.

Regeneron’s marketed products include EYLEA and EYLEA HD for certain retinal diseases; Dupixent, developed and commercialized with Sanofi, for multiple allergic and inflammatory conditions; Libtayo for certain cancers; Praluent for high cholesterol; Kevzara for rheumatoid arthritis and other inflammatory diseases; Evkeeza for homozygous familial hypercholesterolemia; and Veopoz for a rare immune-mediated disorder.